Recurrent angina after revascularization: An emerging problem for the clinician

Coronary Artery Disease

Volumn 15, Issue SUPPL. 1, 2004, Pages

  Lemos, Pedro A ^a   Hoye, Angela ^a   Serruys, Patrick W ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Angina; Angioplasty; Bypass surgery; Pharmacologic agents

Indexed keywords

ACETYLSALICYLIC ACID; ANTIANGINA PECTORIS AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; NITRATE; SARPOGRELATE; TRIMETAZIDINE;

ANGINA PECTORIS; ATHEROSCLEROSIS; BYPASS SURGERY; DISEASE COURSE; GRAFT FAILURE; HEART MUSCLE REVASCULARIZATION; HUMAN; PERCUTANEOUS CORONARY INTERVENTION; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PRIORITY JOURNAL; RECURRENT DISEASE; REOPERATION; RESTENOSIS; REVIEW; SYMPTOM;

ANGINA PECTORIS; HUMANS; MYOCARDIAL REVASCULARIZATION; RECURRENCE;

EID: 3042751492     PISSN: 09546928     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (70)

1. Birkmeyer JD, Siewers AE, Finlayson EV, Stukel TA, Lucas FL, Batista I, et al. Hospital volume and surgical mortality in the United States. N Engl J Med 2002; 346:1128-1137.
2. Serruys PW, Unger F, Sousa JE, Jatene A, Bonnier HJ, Schonberger JP, et al. Comparison of coronary-artery bypass surgery and stenting for the treatment of multivessel disease. N Engl J Med 2001; 344:1117-1124.
3. Eagle KA, Guyton RA, Davidoff R, Ewy GA, Fonger J, Gardner TJ, et al. ACC/AHA Guidelines for Coronary Artery Bypass Graft Surgery: A Report of the American College of Cardiology/American Heart Asoociation Task Force on Practice Guidelines (Committee to Revise the 1991 Guidelines for Coronary Artery Bypass Graft Surgery). American College of Cardiology/American Heart Association. J Am Coll Cardiol 1999; 34:1262-1347.
4. Smith SC Jr, Dove JT, Jacobs AK, Kennedy JW, Kereiakes D, Kern MJ, et al. ACC/AHA guidelines of percutaneous coronary interventions (revision of the 1993 PTCA guidelines. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (committee to revise the 1993 guidelines for percutaneous transluminal coronary angioplasty). J Am Coll Cardiol 2001; 37:2215-2239.
5. Passamani E, Davis KB, Gillespie MJ, Killip T. A randomized trial of coronary artery bypass surgery. Survival of patients with a low ejection fraction. N Engl J Med 1985; 312:1665-1671.
6. Caracciolo EA, Davis KB, Sopko G, Kaiser GC, Corley SD, Schaff H, et al. Comparison of surgical and medical group survival in patients with left main equivalent coronary artery disease. Long-term CASS experience. Circulation 1995; 91:2335-2344.
7. Caracciolo EA, Davis KB, Sopko G, Kaiser GC, Corley SD, Schaff H, et al. Comparison of surgical and medical group survival in patients with left main coronary artery disease. Long-term CASS experience. Circulation 1995; 91:2325-2334.
8. Lagerqvist B, Husted S, Kontny F, Naslund U, Stahle E, Swahn E, et al. A long-term perspective on the protective effects of an early invasive strategy in unstable coronary artery disease: two-year follow-up of the FRISC-II invasive study. J Am Coll Cardiol 2002; 40:1902-1914.
9. Cannon CP, Weintraub WS, Demopoulos LA, Vicari R, Frey MJ, Lakkis N, et al. Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban. N Engl J Med 2001; 344:1879-1887.
10. Zahn R, Schiele R, Schneider S, Gitt AK, Wienbergen H, Seidl K et al. Decreasing hospital mortality between 1994 and 1998 in patients with acute myocardial infarction treated with primary angioplasty but not in patients treated with intravenous thrombolysis. Results from the pooled data of the Maximal Individual Therapy in Acute Myocardial Infarction (MITRA) Registry and the Myocardial Infarction Registry (MIR). J Am Coll Cardiol 2000; 36:2064-2071.
11. Weaver WD, Simes RJ, Betriu A, Grines CL, Zijlstra F, Garcia E, et al. Comparison of primary coronary angioplasty and intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review. JAMA 1997; 278:2093-2098.
12. Grines C, Patel A, Zijlstra F, Weaver WD, Granger C, Simes RJ. Primary coronary angioplasty compared with intravenous thrombolytic therapy for acute myocardial infarction: six-month follow up and analysis of individual patient data from randomized trials. Am Heart J 2003; 145:47-57.
13. Kjoller-Hansen L, Steffensen R, Grande P. The Angiotensin-converting Enzyme Inhibition Post Revascularization Study (APRES). J Am Coll Cardiol 2000; 35:881-888.
14. Hung J. Aspirin for cardiovascular disease prevention. Med J Aust 2003; 179:147-152.
15. Serruys PW, de Feyter P, Macaya C, Kokott N, Puel J, Vrolix M, et al. Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: a randomized controlled trial. JAMA 2002; 287:3215-3222.
16. Manchanda SC. Treatment of stable angina with low dose diltiazem in combination with the metabolic agent trimetazidine. Int J Cardiol 2003; 88:83-89.
17. Marzilli M, Klein W. Efficiency and feasibility of trimetazidine in stable angina: a meta-analysis of randomized, double blind, controlled trials. Coron Artery Dis 2003; 14:171-178.
18. Holubkov R, Laskey WK, Haviland A, Slater JC, Bourassa MG, Vlachos HA, et al. Angina 1 year after percutaneous coronary intervention: a report from the NHLBI Dynamic Registry. Am Heart J 2002; 144:826-833.
19. Rodriguez A, Bernardi V, Navia J, Baldi J, Grinfeld L, Martinez J, et al. Argentine Randomized Study: Coronary Angioplasty with Stenting versus Coronary Bypass Surgery in patients with Multiple-Vessel Disease (ERACI II): 30-day and one-year follow-up results. ERACI II Investigators. J Am Coll Cardiol 2001; 37:51-58.
20. SOS Investigators. Coronary artery bypass surgery versus percutaneous coronary intervention with stent implantation in patients with multivessel coronary artery disease (the Stent or Surgery trial): a randomised controlled trial. Lancet 2002; 360:965-970.
21. Hueb W. Medical, Angioplasty and Surgical Study (MASS) 2. American College of Cardiology 50th Annual Scientific Session 2001.
22. van der Meer J, Hillege HL, van Gilst WH, Brutel de la Riviere A, Dunselman PH, Fidler V, et al. A comparison of internal mammary artery and saphenous vein grafts after coronary artery bypass surgery. No difference in 1-year occlusion rates and clinical outcome. CABADAS Research Group of the Interuniversity Cardiology Institute of The Netherlands. Circulation 1994; 90:2367-2374.
23. Kim KB, Lim C, Lee C, Chae IH, Oh BH, Lee MM, et al. Off-pump coronary artery bypass may decrease the patency of saphenous vein grafts. Ann Thorac Surg 2001; 72:S1033-S1037.
24. Manninen HI, Jaakkola P, Suhonen M, Rehnberg S, Vuorenniemi R, Matsi PJ. Angiographic predictors of graft patency and disease progression after coronary artery bypass grafting with arterial and venous grafts. Ann Thorac Surg 1998; 66:1289-1294.
25. Schwartz L, Kip KE, Frye RL, Alderman EL, Schaff HV, Detre KM. Coronary bypass graft patency in patients with diabetes in the Bypass Angioplasty Revascularization Investigation (BARI). Circulation 2002; 106:2652-2658.
26. FitzGibbon GM, Leach AJ, Kafka HP, Keon WJ. Coronary bypass graft fate: long-term angiographic study. J Am Coll Cardiol 1991; 17:1075-1080.
27. Fabricius AM, Gerber W, Hanke M, Garbade J, Autschbach R, Mohr FW. Early angiographic control of perioperative ischemia after coronary artery bypass grafting. Eur J Cardiothorac Surg 2001; 19:853-858.
28. Fuster V, Chesebro JJ. Aortocoronary artery vein-graft disease: experimental and clinical approach for the understanding of the role of platelets and platelet inhibitors. Circulation 1985; 72:V65-V70.
29. Motwani JG, Topol EJ. Aortocoronary saphenous vein graft disease: pathogenesis, predisposition, and prevention. Circulation 1998; 97:916-931.
30. Tsui JC, Dashwood MR. Recent strategies to reduce vein graft occlusion: a need to limit the effect of vascular damage. Eur J Vasc Endovasc Surg 2002; 23:202-208.
31. Thatte HS, Khuri SF. The coronary artery bypass conduit: I. Intraoperative endothelial injury and its implication on graft patency. Ann Thorac Surg 2001; 72:S2245-S2252; discussion S2267-S2270.
32. Lemos PA, Serruys PW, Sousa JE. Drug-eluting stents: cost versus clinical benefit. Circulation 2003; 107:3003-3007.
33. Serruys PW, Luijten HE, Beatt KJ, Geuskens R, de Feyter PJ, van den Brand M, et al. Incidence of restenosis after successful coronary angioplasty: a time-related phenomenon. A quantitative angiographic study in 342 consecutive patients at 1, 2, 3, and 4 months. Circulation 1988; 77:361-371.
34. Meireles GCX, Lemos PA, Ambrose JA, Ribeiro E, Horta PE, Perin M, et al. Luminal Recovery From 6 to 12 months After Implantation of "Thicker- Strut" Coronary Stents. Am J Cardiol (in press).
35. Kimura T, Abe K, Shizuta S, Odashiro K, Yoshida Y, Sakai K, et al. Long-term clinical and angiographic follow-up after coronary stent placement in native coronary arteries. Circulation 2002; 105:2986-2991.
36. Zimmet P, Alberti KG, Shaw J. Global and societal implications of the diabetes epidemic. Nature 2001; 414:782-787.
37. de Feyter PJ, Vos J, Rensing BJ. Anti-restenosis trials. Curr Interv Cardiol Rep 2000; 2:326-331.
38. Brophy JM, Belisle P, Joseph L. Evidence for use of coronary stents. A hierarchical bayesian meta-analysis. Ann Intern Med 2003; 138:777-786.
39. Colombo A, Drzewiecki J, Banning A, Grube E, Hauptmann K, Silber S, et al. Randomized study to assess the effectiveness of slow- and moderate-release polymer-based paclitaxel-eluting stents for coronary artery lesions. Circulation 2003; 108:788-794.
40. Lemos PA, Serruys PW, van Domburg RT, Saia F, Arampatzis CA, Hoye A, et al. Unrestricted Utilization of Sirolimus-Eluting Stents Compared to Conventional Bare Stent Implantation in the "Real World". The Rapamycin-Eluting Stent Evaluated At Rotterdam Cardiology Hospital (RESEARCH) registry. Circulation (in press).
41. Morice MC, Serruys PW, Sousa JE, Fajadet J, Ban Hayashi E, Perin M, et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med 2002; 346:1773-1780.
42. Park SJ, Shim WH, Ho DS, Raizner AE, Park SW, Hong MK, et al. A paclitaxel-eluting stent for the prevention of coronary restenosis. N Engl J Med 2003; 348:1537-1545.
43. Moses JW, Leon MB, Popma JJ, Fitzgerald PJ, Holmes DR, O'Shaughnessy C, et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 2003; 349:1315-1323.
44. Schofer J, Schluter M, Gershlick AH, Wijns W, Garcia E, Schampaert E, et al. Sirolimus-eluting stents for treatment of patients with long atherosclerotic lesions in small coronary arteries: double-blind, randomised controlled trial (E-SIRIUS). Lancet 2003; 362:1093-1099.
45. Kroncke GM, Kosolcharoen P, Clayman JA, Peduzzi PN, Detre K, Takaro T. Five-year changes in coronary arteries of medical and surgical patients of the Veterans Administration Randomized Study of Bypass Surgery. Circulation 1988; 78:144-150.
46. Hwang MH, Meadows WR, Palac RT, Piao ZE, Pifarre R, Loeb HS, et al. Progression of native coronary artery disease at 10 years: insights from a randomized study of medical versus surgical therapy for angina. J Am Coll Cardiol 1990; 16:1066-1070.
47. Kuntz RE. Importance of considering atherosclerosis progression when choosing a coronary revascularization strategy: the diabetes-percutaneous transluminal coronary angioplasty dilemma. Circulation 1999; 99:847-851.
48. Klein LW, Avula SB, Uretz E, Qurashi MA, Calvin JE, Parrillo JE. Utility of various clinical, noninvasive, and invasive procedures for determining the causes of recurrence of myocardial ischemia or infarction > or =1 year after percutaneous transluminal coronary angioplasty. Am J Cardiol 1995; 75:1003-1006.
49. Versaci F, Gaspardone A, Tomai F, Proietti I, Crea F, Chiariello L, et al. Chest pain after coronary artery stent implantation. Am J Cardiol 2002; 89:500-504.
50. Panting JR, Gatehouse PD, Yang GZ, Grothues F, Firmin DN, Collins P, et al. Abnormal subendocardial perfusion in cardiac syndrome X detected by cardiovascular magnetic resonance imaging. N Engl J Med 2002; 346:1948-1953.
51. Panza JA. Myocardial ischemia and the pains of the heart. N Engl J Med 2002; 346:1934-1935.
52. Gibbons RJ, Chatterjee K, Daley J, Douglas JS, Fihn SD, Gardin JM, et al. ACC/AHA/ACP-ASIM guidelines for the management of patients with chronic stable angina: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Patients With Chronic Stable Angina). J Am Coll Cardiol 1999; 33:2092-2197.
53. Kinugawa T, Fujita M, Lee JD, Nakajima H, Hanada H, Miyamoto S. Effectiveness of a novel serotonin blocker, sarpogrelate, for patients with angina pectoris. Am Heart J 2002; 144:E1.
54. Morrison DA, Sethi G, Sacks J, Henderson W, Grover F, Sedlis S et al. Percutaneous coronary intervention versus coronary artery bypass graft surgery for patients with medically refractory myocardial ischemia and risk factors for adverse outcomes with bypass: a multicenter, randomized trial. Investigators of the Department of Veterans Affairs Cooperative Study #385, the Angina With Extremely Serious Operative Mortality Evaluation (AWESOME). J Am Coll Cardiol 2001; 38:143-149.
55. Morrison DA, Sethi G, Sacks J, Henderson W, Grover F, Sedlis S, et al. Percutaneous coronary intervention versus coronary bypass graft surgery for patients with medically refractory myocardial ischemia and risk factors for adverse outcomes with bypass: The VA AWESOME multicenter registry: comparison with the randomized clinical trial. J Am Coll Cardiol 2002; 39:266-273.
56. Morrison DA, Sethi G, Sacks J, Henderson WG, Grover F, Sedlis S, et al. Percutaneous coronary intervention versus repeat bypass surgery for patients with medically refractory myocardial ischemia: AWESOME randomized trial and registry experience with post-CABG patients. J Am Coll Cardiol 2002; 40:1951-1954.
57. Cole JH, Jones EL, Craver JM, Guyton RA, Morris DC, Douglas JS, et al. Outcomes of repeat revascularization in diabetic patients with prior coronary surgery. J Am Coll Cardiol 2002; 40:1968-1975.
58. Bourassa MG, Detre KM, Johnston JM, Vlachos HA, Holubkov R. Effect of prior revascularization on outcome following percutaneous coronary intervention; NHLBI Dynamic Registry. Eur Heart J 2002; 23:1546-1555.
59. Grube E, Schofer JJ, Webb J, Schuler G, Colombo A, Sievert H, et al. Evaluation of a balloon occlusion and aspiration system for protection from distal embolization during stenting in saphenous vein grafts. Am J Cardiol 2002; 89:941-945.
60. Stone GW, Rogers C, Hermiller J, Feldman R, Hall P, Haber R, et al. Randomized comparison of distal protection with a filter-based catheter and a balloon occlusion and aspiration system during percutaneous intervention of diseased saphenous vein aorto-coronary bypass grafts. Circulation 2003; 108:548-553.
61. Stone GW, Rogers C, Ramee S, White C, Kuntz RE, Popma JJ, et al. Distal filter protection during saphenous vein graft stenting: technical and clinical correlates of efficacy. J Am Coll Cardiol 2002; 40:1882-1888.
62. Savage MP, Douglas JS Jr, Fischman DL, Pepine CJ, King SB 3rd, Werner JA, et al. Stent placement compared with balloon angioplasty for obstructed coronary bypass grafts. Saphenous Vein De Novo Trial Investigators. N Engl J Med 1997; 337:740-747.
63. Mehran R, Dangas G, Abizaid AS, Mintz GS, Lansky AJ, Satler LF, et al. Angiographic patterns of in-stent restenosis: classification and implications for long-term outcome. Circulation 1999; 100:1872-1878.
64. French MH, Faxon DP. Update on radiation for restenosis. Rev Cardiovasc Med 2002; 3:1-6.
65. Waksman R, Lew R, Ajani AE, Pichard AD, Satler LF, Kent KM, et al. Repeat intracoronary radiation for recurrent in-stent restenosis in patients who failed intracoronary radiation. Circulation 2003; 108:654-656.
66. Saia F, Lemos PA, Sianos G, Degertekin M, Lee CH, Arampatzis CA et al. Effectiveness of sirolimus-eluting stent implantation for recurrent in-stent restenosis after brachytherapy. Am J Cardiol 2003; 92:200-203.
67. Hoye A, Lemos PA, Arampatzis CA, Saia F, Tanabe K, Degertekin M, et al. Effectiveness of the Sirolimus-eluting Stent in the Treatment of Patients with a Prior History of Coronary Artery Bypass Graft Surgery. Coron Artery Dis (in press).
68. Tanabe K, Serruys PW, Grube E, Smits PC, Selbach G, van der Giessen WJ, et al. TAXUS III Trial: in-stent restenosis treated with stent-based delivery of paclitaxel incorporated in a slow-release polymer formulation. Circulation 2003; 107:559-564.
69. Sousa JE, Costa MA, Abizaid A, Sousa AG, Feres F, Mattos LA, et al. Sirolimus-eluting stent for the treatment of in-stent restenosis: a quantitative coronary angiography and three-dimensional intravascular ultrasound study. Circulation 2003; 107:24-27.
70. Degertekin M, Regar E, Tanabe K, Smits PC, van der Giessen WJ, Carlier SG, et al. Sirolimus-eluting stent for treatment of complex in-stent restenosis. The first clinical experience. J Am Coll Cardiol 2003; 41:184-189.